Meet Replior at OCT Europe 2026

About the session:

Every day of Phase III delay costs roughly $56,000, and much of the signal sponsors pay for is lost to three sources of noise that are largely within our control: patient attrition (Phase III dropouts frequently exceed 30%), measurement variance in subjective endpoints (placebo response of 20–40% is the norm in recall-based PROs), and unmeasured environmental exposure (light is still captured, if at all, by a checkbox).

This session presents a practical framework for addressing each source with measurement rather than molecules, combining behavioral-science eCOA with sensor-based digital endpoints — ScratchSense for continuous itch and sleep quantification, and RaySense for UV, visible, and infrared exposure. The framework is applicable across dermatology, pruritus-driven indications (atopic dermatitis, CKD-associated pruritus, chronic urticaria, prurigo nodularis), lupus, chronobiology, and photosensitive-drug safety programs. The session includes a live ScratchSense demonstration showing the gap between recall-based itch reporting and continuous objective measurement.